Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Non-Current Assets (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Non-Current Assets for 6 consecutive years, with $251194.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets fell 14.62% to $251194.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.0 million, a 29.39% decrease, with the full-year FY2024 number at $252550.0, down 39.76% from a year prior.
  • Non-Current Assets was $251194.0 for Q3 2025 at Ensysce Biosciences, down from $292860.0 in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $12.8 million in Q1 2021 to a low of $210883.0 in Q1 2025.
  • A 5-year average of $1.1 million and a median of $502550.0 in 2023 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: soared 19100.1% in 2021, then tumbled 94.41% in 2022.
  • Ensysce Biosciences' Non-Current Assets stood at $754756.0 in 2021, then fell by 22.37% to $585883.0 in 2022, then fell by 28.45% to $419217.0 in 2023, then crashed by 39.76% to $252550.0 in 2024, then fell by 0.54% to $251194.0 in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Non-Current Assets are $251194.0 (Q3 2025), $292860.0 (Q2 2025), and $210883.0 (Q1 2025).